JPWO2022047260A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022047260A5
JPWO2022047260A5 JP2023513975A JP2023513975A JPWO2022047260A5 JP WO2022047260 A5 JPWO2022047260 A5 JP WO2022047260A5 JP 2023513975 A JP2023513975 A JP 2023513975A JP 2023513975 A JP2023513975 A JP 2023513975A JP WO2022047260 A5 JPWO2022047260 A5 JP WO2022047260A5
Authority
JP
Japan
Prior art keywords
heterocycloalkyl
alkyl
cycloalkyl
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023513975A
Other languages
English (en)
Japanese (ja)
Other versions
JP7846091B2 (ja
JP2023540270A5 (https=
JP2023540270A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/048101 external-priority patent/WO2022047260A1/en
Publication of JP2023540270A publication Critical patent/JP2023540270A/ja
Publication of JP2023540270A5 publication Critical patent/JP2023540270A5/ja
Publication of JPWO2022047260A5 publication Critical patent/JPWO2022047260A5/ja
Application granted granted Critical
Publication of JP7846091B2 publication Critical patent/JP7846091B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023513975A 2020-08-28 2021-08-27 複素環式化合物およびその使用 Active JP7846091B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063072056P 2020-08-28 2020-08-28
US63/072,056 2020-08-28
PCT/US2021/048101 WO2022047260A1 (en) 2020-08-28 2021-08-27 Heterocyclic compounds and uses thereof

Publications (4)

Publication Number Publication Date
JP2023540270A JP2023540270A (ja) 2023-09-22
JP2023540270A5 JP2023540270A5 (https=) 2024-09-04
JPWO2022047260A5 true JPWO2022047260A5 (https=) 2024-09-04
JP7846091B2 JP7846091B2 (ja) 2026-04-14

Family

ID=80353317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513975A Active JP7846091B2 (ja) 2020-08-28 2021-08-27 複素環式化合物およびその使用

Country Status (7)

Country Link
US (2) US12365676B2 (https=)
EP (1) EP4203952A4 (https=)
JP (1) JP7846091B2 (https=)
CN (1) CN116368130A (https=)
AU (1) AU2021331492A1 (https=)
CA (1) CA3191279A1 (https=)
WO (1) WO2022047260A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210006356A (ko) 2018-04-04 2021-01-18 아비나스 오퍼레이션스, 인코포레이티드 단백질분해 조절제 및 연관된 사용 방법
US12479834B2 (en) 2019-11-29 2025-11-25 Taiho Pharmaceutical Co., Ltd. Phenol compound or salt thereof
CN116368130A (zh) 2020-08-28 2023-06-30 金橘生物科技公司 杂环化合物及其用途
BR112023015976A2 (pt) * 2021-02-09 2023-12-12 Medshine Discovery Inc Compostos de anel aromático de pirimidina
WO2022214102A1 (zh) * 2021-04-09 2022-10-13 杭州英创医药科技有限公司 作为kras g12d抑制剂的杂环化合物
JP2024517695A (ja) * 2021-04-29 2024-04-23 アムジエン・インコーポレーテツド 複素環式化合物及び使用方法
JP2024517693A (ja) * 2021-04-29 2024-04-23 アムジエン・インコーポレーテツド 2-アミノベンゾチアゾール化合物及びその使用方法
CN117222650A (zh) * 2021-04-30 2023-12-12 劲方医药科技(上海)有限公司 吡啶或嘧啶并环类化合物,其制法与医药上的用途
CN117500799A (zh) * 2021-06-09 2024-02-02 伊莱利利公司 作为kras g12d抑制剂的取代的稠合吖嗪
JP2024520791A (ja) * 2021-06-10 2024-05-24 レデックス・ファーマ・パブリック・リミテッド・カンパニー 化合物
EP4373822A2 (en) 2021-07-23 2024-05-29 Theras Inc. Compositions and methods for inhibition of ras
US20240409558A1 (en) * 2021-09-13 2024-12-12 Biomea Fusion, Inc. Irreversible inhibitors of kras
WO2023061294A1 (zh) * 2021-10-13 2023-04-20 再鼎医药(上海)有限公司 含氮杂环类衍生物调节剂、其制备方法及应用
WO2023072188A1 (zh) * 2021-10-29 2023-05-04 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
EP4405337A4 (en) * 2021-11-30 2025-11-26 Beta Pharma Inc Fused pyrimidine derivatives as kras oncoprotein inhibitors
IL314486A (en) * 2022-02-03 2024-09-01 Mirati Therapeutics Inc Quinazoline compounds inhibit PAN-KRAS
AU2023218370B2 (en) 2022-02-09 2024-11-28 Quanta Therapeutics, Inc. Kras modulators and uses thereof
AU2023222076A1 (en) * 2022-02-16 2024-08-15 Amgen Inc. Quinazoline compounds and use thereof as inhibtors of mutant kras proteins
EP4479398A1 (en) * 2022-02-16 2024-12-25 Amgen Inc. Quinazoline compounds and use thereof as inhibtors of mutant kras proteins
KR20240163107A (ko) 2022-03-11 2024-11-18 컴쿼트 바이오사이언시즈 인크. 헤테로환 화합물 및 이의 용도
JP7676677B2 (ja) * 2022-03-25 2025-05-14 イーライ リリー アンド カンパニー Kras阻害剤
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔5,4-b〕吡啶malt-1抑制劑
AU2023264608A1 (en) * 2022-05-04 2024-11-07 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
IL317601A (en) 2022-05-25 2025-02-01 Quanta Therapeutics Inc Pyrimidine-based modulators and their uses
JP2025524597A (ja) * 2022-07-07 2025-07-30 ベイジン スウィッツアランド ゲゼルシャフト ミット ベシュレンクテル ハフツング 複素環式化合物、その組成物、及びそれによる処置方法
CN119768409A (zh) * 2022-08-25 2025-04-04 北京加科思新药研发有限公司 K-Ras突变蛋白抑制剂
TW202416976A (zh) * 2022-09-16 2024-05-01 大陸商南京明德新藥研發有限公司 含六氫螺環[環丙烷—1,2'—吡咯𠯤]的化合物
WO2024061365A1 (zh) * 2022-09-22 2024-03-28 成都奥睿药业有限公司 嘧啶并环类化合物及其制备方法与用途
CN121419983A (zh) 2023-01-26 2026-01-27 阿尔维纳斯运营股份有限公司 基于小脑蛋白的kras降解protac及其相关用途
WO2024192424A1 (en) 2023-03-15 2024-09-19 Quanta Therapeutics, Inc. Kras modulators and uses thereof
EP4688792A1 (en) * 2023-03-31 2026-02-11 Eli Lilly and Company Kras inhibitors
WO2025085748A1 (en) 2023-10-20 2025-04-24 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW212792B (https=) * 1991-09-13 1993-09-11 Shell Internat Res Schappej B V
WO2004054977A1 (en) 2002-12-13 2004-07-01 Cytopia Pty Ltd Nicotinamide-based kinase inhibitors
EA201000316A1 (ru) * 2007-09-12 2010-10-29 ВАЙЕТ ЭлЭлСи Производные изохинолинила и изоиндолинила в качестве антагонистов гистаминовых рецепторов 3 подтипа
CA2834164A1 (en) * 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused benzoxazinones as ion channel modulators
EP2836482B1 (en) 2012-04-10 2019-12-25 The Regents of The University of California Compositions and methods for treating cancer
AU2014331794C1 (en) 2013-10-10 2019-09-12 Araxes Pharma Llc Inhibitors of KRAS G12C
JP2018513853A (ja) * 2015-04-10 2018-05-31 アラクセス ファーマ エルエルシー 置換キナゾリン化合物およびその使用方法
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
EA201992781A1 (ru) 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
AU2018271990A1 (en) * 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
HRP20230377T1 (hr) 2017-11-15 2023-06-23 Mirati Therapeutics, Inc. Inhibitori mutacije kras g12c
TW202012415A (zh) 2018-05-08 2020-04-01 瑞典商阿斯特捷利康公司 化學化合物
TW202033518A (zh) 2018-10-15 2020-09-16 美商美國禮來大藥廠 Kras g12c 抑制劑
PT3735299T (pt) 2018-11-09 2024-11-25 Hoffmann La Roche Compostos de anéis fundidos
AU2019388998A1 (en) 2018-11-29 2021-06-03 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2020238791A1 (zh) 2019-05-24 2020-12-03 江苏恒瑞医药股份有限公司 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
CN112300153B (zh) 2019-07-26 2023-06-13 博瑞生物医药(苏州)股份有限公司 一种杂环化合物、药物组合物和用途
TWI752580B (zh) 2019-08-07 2022-01-11 大陸商北京加科思新藥研發有限公司 Kras突變蛋白抑制劑
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
ES2929700T3 (es) 2019-12-11 2022-12-01 Lilly Co Eli Inhibidores de KRas g12c
CN116194456B (zh) 2020-04-30 2025-08-29 上海科州药物股份有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
CN116368130A (zh) 2020-08-28 2023-06-30 金橘生物科技公司 杂环化合物及其用途
CN114380827A (zh) 2020-10-22 2022-04-22 贝达药业股份有限公司 Kras g12c抑制剂及其在医药上的应用
US20240059710A1 (en) 2020-11-20 2024-02-22 Jacobio Pharmaceuticals Co., Ltd. KRAS G12D Inhibitors
US20240109893A1 (en) 2020-12-22 2024-04-04 Shanghai Kechow Pharma, Inc. Preparation and application method of heterocyclic compounds as kras inhibitor
CN113999226B (zh) 2020-12-22 2023-01-06 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
US20240140957A1 (en) 2021-01-08 2024-05-02 Beigene Switzerland Gmbh Bridged compounds as kras g12d inhibitor and degrader and the use thereof
WO2022170999A1 (zh) 2021-02-09 2022-08-18 南京明德新药研发有限公司 吡啶[4,3-d]嘧啶类化合物
WO2022173870A1 (en) 2021-02-09 2022-08-18 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
BR112023015976A2 (pt) 2021-02-09 2023-12-12 Medshine Discovery Inc Compostos de anel aromático de pirimidina
AU2022224511A1 (en) 2021-02-16 2023-08-10 Lawrence Livermore National Security, Llc Compositions and methods for inhibition of ras
WO2022184178A1 (en) 2021-03-05 2022-09-09 Jacobio Pharmaceuticals Co., Ltd. Kras g12d inhibitors
WO2022221739A1 (en) 2021-04-16 2022-10-20 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12d mutant
CN115490709A (zh) 2021-04-30 2022-12-20 四川海思科制药有限公司 一种krasg12d抑制剂及其在医药上的应用
WO2022247760A1 (zh) 2021-05-22 2022-12-01 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物,及其制备和治疗用途
CN117500799A (zh) 2021-06-09 2024-02-02 伊莱利利公司 作为kras g12d抑制剂的取代的稠合吖嗪
JP2024520791A (ja) 2021-06-10 2024-05-24 レデックス・ファーマ・パブリック・リミテッド・カンパニー 化合物
WO2022266015A1 (en) 2021-06-14 2022-12-22 Kumquat Biosciences Inc. Fused heteroaryl compounds useful as anticancer agents
US20240293558A1 (en) 2021-06-16 2024-09-05 Erasca, Inc. Kras inhibitor conjugates
CN115611923A (zh) 2021-07-12 2023-01-17 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
EP4373822A2 (en) 2021-07-23 2024-05-29 Theras Inc. Compositions and methods for inhibition of ras
WO2023018699A1 (en) 2021-08-10 2023-02-16 Erasca, Inc. Selective kras inhibitors
TW202328124A (zh) 2021-08-18 2023-07-16 大陸商北京加科思新藥研發有限公司 1,4-氧雜氮雜環庚烷衍生物及其用途

Similar Documents

Publication Publication Date Title
JPWO2022047260A5 (https=)
JPWO2022173870A5 (https=)
IL304986A (en) Compositions and methods for inhibition of ras
CA2472372A1 (en) Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
JP7358484B2 (ja) 併用療法
JP5579715B2 (ja) cdk阻害剤および抗悪性腫瘍剤を含む治療用組合せ
Moon et al. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients
RU2000102359A (ru) Фармацевтическая композиция, обладающая улучшенным противораковым действием и/или сниженными побочными эффектами, содержащая противораковый агент и производное гидроксамовой кислоты
JP2004517843A5 (https=)
RU98104448A (ru) Оральные быстрорастворяющиеся композиции агонистов допамина
AU2022203683B2 (en) Stable, concentrated radionuclide complex solutions
EP3681503A1 (en) Protein kinase c inhibitors for treatment of uveal melanoma
CA2909510A1 (en) Methods and compositions for gamma-glutamyl cycle modulation
JPWO2021093839A5 (https=)
Friedman et al. Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts
JP2021518348A5 (https=)
JP2004510734A (ja) ディスタマイシン誘導体を含む抗腫瘍療法
KR920016418A (ko) Nmda 길항제
RU2020133811A (ru) Фармацевтические комбинации
Hainsworth et al. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma
NZ533940A (en) Combinations comprising epothilones and anti-metabolites
RU2010129038A (ru) Соединения, предназначенные для лечения рака
TW202517302A (zh) 穩定的、濃縮的放射性核種錯合物溶液
RU2005136426A (ru) 5-гидроксииндолы с пиридин-n-оксидными группами и их применение в качестве ингибиторов фосфодиэстеразы 4
RU2008102912A (ru) Сочетание ингибиторов бетта-лактазмы бициклического 6-алкилиденпенема с бетта-лактанным антибиотиком: антибиотик широкого спектра